ChartMill · Oct 27, 2026
Premarket Movers: Gainers and Losers Ahead of Today's US Open
Premarket movers ahead of the US open: BRAI, OPENZ, NEXR, XXII and AUROW among top gainers, while DVLT, SPRC, ARTV and ACTU lead declines.
AC
NASDAQ · ACTU
Actuate Therapeutics Inc
Healthcare · Biotechnology
$0.37
Down-$0.01 (-3.21%)
Updated Oct 30, 2026, 5:56 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 86.93M
- P/E ratio
- -3.32
- Dividend yield
- 0.00%
- 52-week range
- $0.35 – $7.90
- Volume
- 814.07K
- Avg. volume
- 71.29K
Price performance · ACTU
ACTU price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
ACTU closed at $0.37 after 21 trading sessions, down 58.28% for the selected period.
- Last close
- $0.37
- Period change
- -58.28%
- Period low
- $0.37
- Period high
- $0.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $0.3833 | $0.4199 | $0.36 | $0.371 | 814.07K |
| Oct 28, 2026 | $0.4042 | $0.4074 | $0.361 | $0.3833 | 715.71K |
| Oct 27, 2026 | $0.3793 | $0.4378 | $0.35 | $0.3995 | 2.21M |
| Oct 26, 2026 | $0.5071 | $0.60 | $0.4751 | $0.5279 | 236.32K |
| Oct 23, 2026 | $0.53 | $0.5563 | $0.4501 | $0.4752 | 256.15K |
| Oct 22, 2026 | $0.57 | $0.5998 | $0.47 | $0.5162 | 335K |
| Oct 21, 2026 | $0.5976 | $0.6379 | $0.5601 | $0.5622 | 220.57K |
| Oct 20, 2026 | $0.5926 | $0.6618 | $0.5462 | $0.6161 | 166.68K |
| Oct 19, 2026 | $0.661 | $0.7099 | $0.52 | $0.599 | 727.33K |
| Oct 16, 2026 | $0.493 | $0.6399 | $0.47 | $0.605 | 926.16K |
| Oct 15, 2026 | $0.457 | $0.55 | $0.4326 | $0.4999 | 472.15K |
| Oct 14, 2026 | $0.48 | $0.49 | $0.41 | $0.4342 | 439.47K |
| Oct 13, 2026 | $0.66 | $0.66 | $0.4383 | $0.4663 | 974.4K |
| Oct 12, 2026 | $0.60 | $0.6801 | $0.60 | $0.6437 | 285.88K |
| Oct 9, 2026 | $0.641 | $0.6799 | $0.6102 | $0.6102 | 301.19K |
| Oct 8, 2026 | $0.6822 | $0.7241 | $0.6206 | $0.679 | 324.46K |
| Oct 7, 2026 | $0.6431 | $0.7242 | $0.615 | $0.7242 | 637.89K |
| Oct 6, 2026 | $0.89 | $0.89 | $0.7597 | $0.8116 | 337.68K |
| Oct 5, 2026 | $0.85 | $0.9258 | $0.8007 | $0.8749 | 202.23K |
| Oct 2, 2026 | $0.93 | $0.9498 | $0.80 | $0.819 | 96.15K |
| Oct 1, 2026 | $0.7976 | $0.9598 | $0.765 | $0.8892 | 494.41K |
Latest ACTU news
The latest Smart Investors Daily articles mentioning ACTU.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ACTU research
Overview
Company profile and research snapshot.
Company profile
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $21.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | Rodman & Renshaw | Buy | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 27, 2026
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings
Yahoo · Oct 27, 2026
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced the pricing of an underwritten public offering of 30,985,900 shares of its common stock and warrants to purchase up to an aggregate of 15,492,950 shares of its common stock. The public offering price for each set of two shares of comm
Benzinga · Oct 27, 2026
Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings
U.S. stocks climbed Tuesday, led by the Nasdaq and tech shares. Coca-Cola beat Q3 estimates and raised guidance, while AI OKTO surged 74%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
